

Express Mail No.: <u>EL 500 576 595 US</u>

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Palese et al.

Application No.: 09/070,629

Group Art Unit: 1648

Filed: April 30, 1998

Examiner: L. Scheiner

For:

RECOMBINANT INFLUENZA VIRUSES EXPRESSING TUMOR-ASSOCIATED

Attorney Docket No.: 6923-071-999

ANTIGENS AS ANTITUMOR AGENTS

## FEE TRANSMITTAL SHEET

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

The fee required to be filed with the accompanying amendment of even date herewith concerning the above-identified application has been estimated to be \$934.

The claim amendment fee has been estimated as shown below:

	(Col. 1)		(Col. 2)		(Col. 3)	SMALL ENTITY				OTHER THAN A SMALL ENTITY		
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO PREVIOUSLY PAID FOR		PRESENT EXTRA	RATE		ADDIT. FEE	OR	RATE	,	ADDIT. FEE
TOTAL	47	MINUS	20	-	27	_ × 9	\$			× 18	\$	486.00
INDEP.	5	MINUS	3	=	2	× 42	\$			× 84	\$	168.00
☐ FIRST PRESENTATION OF MULTIPLE DEP. CLAIM						140	\$			280	\$	280,00
						TOTAL	\$		OR	TOTAL	\$	934.00

Please charge the required fee to Pennie & Edmonds LLP Deposit Account No. 16-1150. A copy of this sheet is enclosed.

Date October 15, 2002

Respectfully submitted,

PENNIE & EDMONDS LLP 1155 Avenue of Americas New York, N.Y. 10036-2711

(212) 790-9090

**Enclosure** 



**EXPRESS MAIL NO.: EL 500 576 5** 

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Palese et al.

Group Art Unit: 1648

Serial No.: 09/070,629

Examiner: Laurie Scheiner

Filed: April 30, 1998

Attorney Docket No.: 6923-071

For: RECOMBINANT INFLUENZA VIRUSES EXPRESSING TUMOR-ASSOCIATED

ANTIGENS AS ANTI-TUMOR AGENTS

## AMENDMENT UNDER 37 C.F.R. § 1.114

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

In response to the Advisory Action mailed April 8, 2002, and in accordance with Rule 114 of the Rules of Practice, please enter the following amendments and consider the following remarks. Applicants submit that entry of these amendments and remarks is proper since Applicants are submitting concurrently herewith a Request for Continued Examination. Applicants submit herewith: (1) Exhibit A, a copy of the claims as pending after entry of this amendment; (2) an Amendment Fee Transmittal (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; (3) a Petition for Extension of Time (in duplicate), accompanied by the appropriate provision authorizing payment of the required fee; and (4) a Request for Continued Examination with the appropriate fees.

/21/2002 AWDNDAF1 00000044 161150 -